Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun:36:100928.
doi: 10.1016/j.eclinm.2021.100928. Epub 2021 Jun 4.

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Affiliations

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Raul Pellini et al. EClinicalMedicine. 2021 Jun.

Abstract

Background: Literature data suggests that age, gender and body mass index (BMI) could be associated with difference in immune responses to vaccines. The first goal of the study was to analyze the antibody titre seven days after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCWs). The second goal was to analyze how antibody titre changes in correlation with age, gender, BMI and hypertension.

Methods: An immunogenicity evaluation was carried out among HCWs vaccinated at the Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy. All HCWs were asked to be vaccinated by the Italian national vaccine campaign at the beginning of 2021. 260 vaccinated HCWs were enrolled in the study. All eligible participants were assigned to receive the priming dose in two weeks' time and the booster dose exactly 21 days thereafter. Blood and nasopharyngeal swabs were collected at baseline and 7 days after second dose of vaccine. Quantitative measurements of IgG antibodies against S1/S2 antigens of SARS-CoV-2 were performed with a commercial chemiluminescent immunoassay. Presence of SARS-Cov-2 in nasopharyngeal swab was determined by commercial RT-PCR testing.

Findings: 248 HWCs were analyzed, 158 women (63.7%) and 90 men (36.3%). After the second dose of BNT162b2 vaccine, 99.5% of participants developed a humoral immune response. The geometric mean concentration of antibodies among the vaccinated subjects after booster dose (285.9 AU/mL 95% CI: 249.5-327.7) was higher than that of human convalescent sera (39.4 AU/mL, 95% CI: 33.1-46.9), with p<0.0001. Multivariate linear regression analysis of AU/mL by age, gender and BMI multivariate was performed by the inclusion of covariates. This analysis demonstrated that age (p<0.0001) and gender (p = 0.038) are statistically associated with differences in antibody response after vaccination, whereas BMI and hypertension have no statistically significant association (p = 0.078 and p = 0.52 respectively).

Interpretation: 99.5% of HCW developed a humoral immune response and female and young participants seem to have an increased capacity to mount humoral immune responses. BMI and hypertension seem not associated with difference in immune response to the vaccine.

Funding: None.

Keywords: Antibodies; COVID-19; Obesity; SARS-CoV-2; Serum titre; Vaccine.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest to disclose.

Figures

Fig. 1:
Fig. 1
Anti SARS-CoV-2 IgG in vaccinated HCW vs COVID-19 convalescent sera. Sera from vaccinees and convalescents were collected as in methods. Antibody levels were expressed as log10 of concentration in Arbitrary Unit (AU).
Fig. 2:
Fig. 2
Levels of anti SARS-CoV-2 IgG by age (a), gender (b), BMI (c) and hypertension (d). Seven days after booster dose, serum was collected from all participants. Antibody levels were expressed as log10 of concentration in Arbitrary Unit (AU). Age was categorized according to quartiles. Body mass index (BMI) classes were categorized according to Weir CB & Jan A (32). Data on hypertension was collected from self-administered questionnaire.

References

    1. WHO. Draft Landscape of COVID-19 Candidate Vaccines, 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand.... (Accessed 14/02/2021).
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383(27):2603–2615. - PMC - PubMed
    1. Verschoor C.P., Singh P., Russell M.L., Bowdish D.M., Brewer A., Cyr L. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS ONE. 2015;10(6) - PMC - PubMed
    1. Chandrashekar A., Liu J., Martinot A.J., McMahan K., Mercado N.B., Peter L. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020;369(6505):812–817. - PMC - PubMed
    1. Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 2020;383(25):2439–2450. - PMC - PubMed